TPG, a global alternative asset management firm, and AmerisourceBergen Corp., a global pharmaceutical services organization, have acquired OneOncology, a network of oncology practices, from General Atlantic, valuing the company at $2.1 billion.

TPG will acquire a majority interest in OneOncology and AmerisourceBergen will acquire a minority interest in this company. OneOncology’s affiliated practices, physicians and management team will also retain a minority interest in the company. TPG is investing in OneOncology through its U.S. and European late-stage private equity platform, TPG Capital.

“The investment in OneOncology will allow AmerisourceBergen to further deepen our relationships with community oncologists and expand on our solutions in specialty,” says Steven Collis, chairman, president & chief executive officer of AmerisourceBergen. “Our complementary skill sets and focus on operational excellence and innovation uniquely position us to continue to partner and support OneOncology’s network.”

J.P. Morgan Securities LLC is serving as financial advisor to AmerisourceBergen, and Morgan, Lewis & Bockius LLP and Sidley Austin LLP are serving as AmerisourceBergen’s legal advisors. Debevoise & Plimpton LLP and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo PC are serving as legal advisors to TPG, and Guggenheim Securities LLC is also serving as an advisor to the firm. Centerview Partners is serving as financial advisor to OneOncology and General Atlantic, and Paul, Weiss, Rifkind, Wharton & Garrison LLP is serving as OneOncology and General Atlantic’s legal advisor.